Delivery Order 75N91024D00005-75N91024F00002
Award Date
6/17/24
Potential Completion Date
12/16/25
Potential Value
$1.9M
Federal Agency
National Cancer Institute
Awardee
University Of Oklahoma
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,113,527.00, was issued by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the University of Oklahoma (OU) to support the PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM. The contract tasks OU, a public research university, with developing a novel multi-antigen vaccine (TNBCVAX) to prevent triple negative breast cancer. This work is being performed under a Delivery Order contract that is part...
The federal contract award, with ID 75N91019D00020|75N91020F00003, was granted by the National Cancer Institute to the University of Oklahoma Health Sciences Center Division, a public research university in Oklahoma City, Oklahoma. The contract is for the "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS" with a task order titled "URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...
This is a $1,029,991.00 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Oklahoma Health Sciences Center. The order is for the "Further Evaluation of AMHR2-ED Antigens for Epithelial Ovarian Carcinoma" project, which aims to conduct research related to epithelial ovarian cancer. The award is part of the larger PREVENT Preclinical Drug Development Program (PREVENT), an Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle...
This federal contract was awarded by the National Cancer Institute (NCI), part of the Department of Health and Human Services (HHS), to the University of Oklahoma (OU) to support the PREVENT Preclinical Drug Development Program. The $884,341.08 firm-fixed-price contract task order is for the development of an EGFR and KRAS vaccine to prevent lung cancer. Key subcontractors include The Methodist Hospital (doing business as Houston Methodist Hospital) and the Medical College of Wisconsin. The...
This is a $982,258 firm-fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Oklahoma Health Sciences Center (OUHSC) under the PREVENT Cancer Preclinical Drug Development Program, a multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at approximately $149,995,000. The task order is titled "Preventing Lung Adenocarcinoma (LUAD) Using TRAIL Inducing Agent, ONC201" and is part of the PREVENT Efficacy Pool. It does not...
This is a $819,519.17 cost-reimbursement delivery order awarded by the National Cancer Institute, a civilian agency of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ Of Oklahoma Health Sciences Center Division. The order is placed under the Preclinical Agent Development Assays 2012-2016 contract vehicle and supports the development of inhibitors for MPGES-1 and 5-LOX proteins for use as colon cancer chemopreventive agents. This work is part of the agency's...
This is a $909,993.85 firm fixed-price delivery order awarded by the National Cancer Institute (NCI) to the University of Oklahoma Health Sciences Center, a public research university and state-controlled institution of higher learning. The contract is part of the NCI's PREVENT Cancer Preclinical Drug Development Program, an initiative focused on evaluating compounds for the prevention of urinary bladder cancer. Under this delivery order, the University of Oklahoma will conduct research and...
This is a firm fixed price Delivery Order awarded by the National Cancer Institute (NCI) to the University of Oklahoma (OU) for the "Prevention of Colorectal Cancer by ONC201" project. The contract, which is part of the NCI's "PREVENT Cancer Program", has a period of performance from September 2016 to September 2018 and a ceiling value of $221,345. The work is focused on preclinical cancer prevention research, specifically evaluating the efficacy of the drug ONC201 for...